PATENT CLAIM ANALYSIS

Application Number: 16036375
Application Type: Utility
Filing Date: 2018-07
Publication Date: 2018-11
Patent Classification: ["514", "179000"]

Abstract:
The invention provides inhibitors of α-crystallin aggregation and methods of using α-crystallin aggregation inhibitors to, e.g., treat or prevent cataracts in a subject having or at risk of developing cataracts. The invention further provides high throughput methods of screening compounds for modulation of protein thermal stability, the method comprising contacting a protein with each of a plurality of test compounds; and (b) measuring the melting transition (T m ) of the protein in the presence of each of the plurality of test compounds, wherein a compound that decreases or increases the apparent T m  by at least 2 standard deviations is identified as a pharmacological protein chaperone.

Claim (Index 5):
The method of any one of  claims 1 - 4 , wherein the composition is administered topically, subconjunctivally, retrobulbarly, periocularly, subretinally, suprachoroidally, or intraocularly.

Metadata:
- Claim Count in Document: 47.0
- Percentile: 95.0
- Lexical Diversity: 1.69565
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['13944477', '15423359', '15139192', '15221550', '13833008']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7601966362068318
- 35 USC 102 Novelty (BERT): 0.5540170038659875
- Combined Prediction Score: 0.7395786729727474
- Mean Citation Score: 250.22456
- Max Citation Score: 442.4466
- Similarity Product: 244.7677912386417

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test